How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Q1 Earnings Call Highlights
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.2 per share a year ago.
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Exagen Inc. ( XGN ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Ryan Douglas - Investors Relations Officer John Aballi - CEO, President & Director Jeffrey Black - CFO & Corporate Secretary Conference Call Participants Anderson Schock - B. Riley Securities, Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Vidyun Bais - BTIG, LLC, Research Division Andrew Brackmann - William Blair & Company L.L.C.
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago.
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer Conference Call Participants Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division Margarate Elizabeth Boeye - William Blair & Company L.L.C.
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Andrew Brackmann - William Blair Paul Knight - KeyBanc Operator Greetings, and welcome to Exagen Inc. First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
